Aetna · Voclosporin · US health-plan appeal rights

Voclosporin denied as experimental or investigational by Aetna?

Q: How long do I have to appeal a Aetna Voclosporin denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

An experimental denial requires the appeal to cite the FDA approval (if any), peer-reviewed phase III data, and the recognised specialty-society guideline that supports the treatment for your indication.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-09

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Aetna typically requires

Adult ≥18 yr with biopsy-proven ISN/RPS class III, IV, V, or mixed within 24 months. Active disease: UPCR ≥1.5 g/g (≥2 g/g for pure class V). eGFR >45 mL/min/1.73m² (caution 45-60). Used in combination with MMF + low-dose GC. Not concurrent with cyclosporine or tacrolimus. BP-controlled <130/80. Reauth 24 wk with UPCR reduction ≥25%; continued at 12 mo with CRR or sustained PRR.

Source policy: Aetna Clinical Policy Bulletin 0993: Lupkynis (Voclosporin) for Active Lupus Nephritis

What works in the appeal

AURORA-1 Lancet 2021 was specifically designed as voclosporin + MMF + low-dose GC vs MMF + low-dose GC alone — CRR 41% vs 23% at wk 52 (OR 2.65, p<0.0001). FDA Jan 22, 2021 label is ACTIVE LN, NOT post-MMF failure. KDIGO 2024 rec 1.2.1 + EULAR 2025 endorse MMF + CNI (voclosporin or tacrolimus) as INITIAL combination regimen. AURORA-2 36-mo extension confirms sustained CRR with stable eGFR. Class V was eligible in AURORA-1 (mixed III+V or IV+V). Discontinue tacrolimus to permit voclosporin transition — voclosporin has favorable PK profile (no TDM required, fixed dose).

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Aetna appeals

Other denial reasons for Aetna Voclosporin

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-09. Editorial standards: denialhelp.com/authors.